Form 4: Aytu BioPharma Executive Acquires 7,000 Stock Options
SEC Form 4
Jarrett Disbrow, Chief Business Officer of Aytu BioPharma, acquired 7,000 employee stock options on November 6, 2024.
Summary
- On November 6, 2024, Jarrett Disbrow, the Chief Business Officer of Aytu BioPharma, acquired 7,000 employee stock options.
- The exercise price of these options is $1.84.
- The options vest over time, with 1/3 vesting on November 6, 2025, and the remaining options vesting in 24 equal monthly installments starting December 6, 2025.
- The options expire on November 6, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The acquisition of options can be seen as a positive sign, but it's not a definitive indicator of future performance.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates the acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- Shareholders may view the acquisition of stock options by a key executive as a positive sign, aligning management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 11/06/2024 | Date of transaction: Jarrett Disbrow acquired 7,000 employee stock options. |
| 11/06/2025 | 1/3 of the options vest. |
| 12/06/2025 | Remaining options vest in 24 equal monthly installments. |
| 11/06/2034 | Expiration date of the options. |
Keywords
stock options, Aytu BioPharma, Jarrett Disbrow, Chief Business Officer, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.